1. Veracyte Inc. (NASDAQ:VCYT)
Veracyte, Inc. (NASDAQ: VCYT) deserves a place among the top biotech stocks to buy today because it sits in one of the most attractive corners of healthcare: genomic diagnostics. Unlike early-stage biotechnology companies that depend mainly on clinical trial readouts, Veracyte already has a growing commercial engine powered by tests used in cancer and pulmonary disease. Based on the latest available market data, Veracyte traded at $38.48, with a market capitalization of about $3.13 billion, giving it mid-cap biotech exposure with an already established revenue base. The company also appeared in the uploaded screen with an 8.00% 12-week price change, a forward P/E of 20.88, and projected one-year sales growth of 12.21%, making it one of the more balanced names on the list.
The latest numbers make the story even more interesting. In Q1 2026, Veracyte grew total revenue to $139.1 million, up 21% year over year, while testing revenue rose 26% to $135.1 million. Growth was led by Decipher, which increased 30% to $86.5 million, and Afirma, which increased 21% to $46.4 million. Veracyte also generated GAAP net income of $28.7 million and adjusted EBITDA of $42.8 million, equal to 30.8% of revenue. That matters because many biotech names are still deep in cash-burn mode, while Veracyte is showing both growth and profitability. Management also raised 2026 total revenue guidance to $582 million to $592 million, from prior guidance of $570 million to $582 million.
CEO Marc Stapley summed up the quarter by saying Veracyte had a “strong start to the year,” with Decipher and Afirma volume growth surpassing expectations, and he highlighted upcoming launches of Prosigna LDT and TrueMRD as “two of the most significant new products” in the company’s history. That quote is important because it frames Veracyte not just as a current diagnostics grower, but as a company trying to expand into larger opportunities across breast, bladder, prostate, thyroid, and other cancers. The risk is that reimbursement decisions, physician adoption, and competitive molecular testing can always pressure growth. But for investors searching for biotech stocks with real revenue, improving margins, genomic testing exposure, and less binary clinical risk, Veracyte looks like one of the cleaner names to watch in 2026.
READ ALSO: Top 10 Biotech Stocks That Could Explode in 2026 and Top 10 Small-Cap FDA Catalyst Biotech Stocks.
Disclosure: No relevant interests to disclose. This article was originally published on BioTech HealthX.
